| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | NEO | Common Stock | Tax liability | $0 | -14 | -0.03% | $0.00 | 44.9K | Aug 1, 2024 | Direct | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | NEO | Stock Option (Right to Buy) | 1.05K | Aug 1, 2024 | Common Stock | 1.05K | $19.12 | Direct | F3 | |||||
| holding | NEO | Stock Option (Right to Buy) | 1.02K | Aug 1, 2024 | Common Stock | 1.02K | $27.34 | Direct | F4 | |||||
| holding | NEO | Stock Option (Right to Buy) | 516 | Aug 1, 2024 | Common Stock | 516 | $48.99 | Direct | F5 | |||||
| holding | NEO | Stock Option (Right to Buy) | 1.12K | Aug 1, 2024 | Common Stock | 1.12K | $46.10 | Direct | F6 | |||||
| holding | NEO | Stock Option (Right to Buy) | 22.2K | Aug 1, 2024 | Common Stock | 22.2K | $9.45 | Direct | F7 | |||||
| holding | NEO | Stock Option (Right to Buy) | 55.3K | Aug 1, 2024 | Common Stock | 55.3K | $10.05 | Direct | F8 | |||||
| holding | NEO | Stock Option (Right to Buy) | 36.5K | Aug 1, 2024 | Common Stock | 36.5K | $19.65 | Direct | F9 | |||||
| holding | NEO | Performance Stock Unit | 19.5K | Aug 1, 2024 | Common Stock | 19.5K | $0.00 | Direct | F10, F11 | |||||
| holding | NEO | Restricted Stock Unit | 13K | Aug 1, 2024 | Common Stock | 13K | $0.00 | Direct | F11, F12 | |||||
| holding | NEO | Stock Option (Right to Buy) | 42.3K | Aug 1, 2024 | Common Stock | 42.3K | $16.45 | Direct | F13 | |||||
| holding | NEO | Performance Stock Unit | 25.3K | Aug 1, 2024 | Common Stock | 25.3K | $0.00 | Direct | F11, F14 | |||||
| holding | NEO | Restricted Stock Unit | 25.3K | Aug 1, 2024 | Common Stock | 25.3K | $0.00 | Direct | F11, F15 |
| Id | Content |
|---|---|
| F1 | Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the August 1, 2024 vesting of restricted stock. |
| F2 | This balance includes 378 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. |
| F3 | On September 30, 2019, Ms. Olivo was granted 1,394 stock options. The options vested ratably over the first four anniversary dates of the grant date. |
| F4 | On May 1, 2020, Ms. Olivo was granted 1,024 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| F5 | On May 1, 2021, Ms. Olivo was granted 516 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| F6 | On August 1, 2021, Ms. Olivo was granted 1,117 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| F7 | On May 1, 2022, Ms. Olivo was granted 22,222 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| F8 | On September 1, 2022, Ms. Olivo was granted 55,332 stock options. The options vest ratably over the first four anniversary dates of the grant date. |
| F9 | On May 11, 2023, Ms. Olivo was granted 36,508 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| F10 | On May 11, 2023, Ms. Olivo was granted 19,508 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 29,262. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. |
| F11 | Once vested, the shares of common stock are not subject to expiration. |
| F12 | On May 11, 2023, Ms. Olivo was granted 19,508 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. |
| F13 | On February 23, 2024, Ms. Olivo was granted 42,344 stock options. The options vest ratably over the first three anniversary dates of the grant date. |
| F14 | On February 23, 2024, Ms. Olivo was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. |
| F15 | On February 23, 2024, Ms. Olivo was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. |